RxDoctor Payments Data

Thomas Koinis, MD

Family Medicine · Oxford, NCNPI 1467537852

Payments from drug & device makers

$33,704in general payments, 2019–2025

Across 63 payments — averaging $534.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$17K
  • Merck$8K
  • Amgen$5K
  • GSK$4K

What the payments were for

  • Consulting fees$14,60043%
  • Speaking & faculty fees$12,66538%
  • Travel & lodging$4,92815%
  • Food & beverage$1,5114%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi Pasteur Inc.30$16,534
Merck22$8,421
Amgen7$4,548
GSK4$4,200

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,704 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$107,716
Medicare patients
300
Services billed
2,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$83,123
JardianceEmpagliflozin93$82,575
CreonLipase/Protease/Amylase13$43,805
TrulicityDulaglutide16$22,434
OzempicSemaglutide22$20,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,889
MounjaroTirzepatide14$14,560
FarxigaDapagliflozin Propanediol13$8,549
Atorvastatin Calcium570$6,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,352
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,060
Potassium Chloride227$4,736
Albuterol Sulfate HfaAlbuterol Sulfate133$4,439
Breo ElliptaFluticasone/Vilanterol12$4,415
Rosuvastatin Calcium304$3,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$4,200$28,43958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Oxford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →